Cargando…
A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
SGLT2 inhibitors may have a potential to stop the decline of renal function independent of the stage of albuminuria in diabetic kidney disease, and can be a new light in the post‐RAS inhibitor era.[Image: see text]
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077719/ https://www.ncbi.nlm.nih.gov/pubmed/35029051 http://dx.doi.org/10.1111/jdi.13747 |